SGHT — Sight Sciences, Inc.

Summary of Sight Sciences (SGHT) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $20.4 million, a 7% increase year-over-year.
• Interventional Glaucoma Revenue: $19.7 million, up 5% year-over-year, flat sequentially.
• Interventional Dry Eye Revenue: $0.7 million, up from $0.3 million year-over-year, reflecting positive traction in the reimbursed model.
• Gross Margin: 87%, consistent with the previous year; Interventional Glaucoma at 88% and Interventional Dry Eye improved to 68%.
• Operating Expenses: Decreased by 25% to $21.5 million, driven by lower personnel-related expenses and stock-based compensation.
• Net Loss: $4.2 million ($0.08 per share), improved from a net loss of $11.8 million ($0.23 per share) in Q4 2024.
• Cash Position: Ended the quarter with $92 million in cash, down from $120.4 million at the end of 2024.

2. Strategic Updates and Business Highlights

• Market Focus: Shifted terminology from "surgical glaucoma and dry eye" to "Interventional Glaucoma and Interventional Dry Eye" to emphasize earlier procedural interventions.
• TearCare Milestone: Achieved reimbursement milestone with MACs Novitas Solutions and First Coast Service Options, establishing pricing for CPT code 0563T.
• Commercial Strategy: Plans to enhance engagement with high-volume dry eye prescribers and expand outreach to glaucoma customers.
• Interventional Glaucoma: Continued focus on expanding the stand-alone market and combo cataract segment, leveraging the OMNI technology.
• Investment in Infrastructure: Additional investments planned in commercial organization for Interventional Dry Eye to support growth.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: $82 million to $88 million, representing growth of 6% to 14% compared to 2025.
  • Interventional Glaucoma: $77 million to $81 million (2% to 7% growth).
  • Interventional Dry Eye: $5 million to $7 million (compared to $1.6 million in 2025).
• First Quarter 2026 Expectations: Low single-digit growth anticipated for Interventional Glaucoma; approximately $1 million expected for Interventional Dry Eye.
• Adjusted Operating Expenses Guidance: $93 million to $96 million, reflecting a 6% to 9% increase due to targeted investments.

4. Challenges and Points of Concern

• Market Headwinds: The Interventional Glaucoma segment faced challenges from LCD changes affecting multiple procedure combinations, which restricted growth in 2025.
• Cash Usage: Although cash usage was the lowest of the year at $0.4 million, the decrease in cash reserves from $120.4 million to $92 million raises concerns about sustainability.
• Potential Reimbursement Changes: Anticipated changes to goniotomy codes by the AMA could negatively impact reimbursement rates for certain procedures starting in 2028.

5. Notable Q&A Insights

• Guidance Clarification: Management emphasized a stable market for Interventional Glaucoma and cautious optimism for Interventional Dry Eye, with no additional market access wins factored into guidance.
• Market Growth Assumptions: The underlying market growth for Interventional Glaucoma is expected to be low to mid-single digits.
• TearCare Peak Sales Potential: While no specific figures were provided, management acknowledged the significant market opportunity and potential for procedural interventions over traditional drop treatments.
• Sales Strategy: The company is focusing on activating the stand-alone glaucoma market by modeling after successful cataract surgery workflows to enhance procedural adoption.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Sight Sciences' performance and outlook.